Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
Systemic lupus erythematosus
•
Cyclophosphamide
•
General Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Latent Tuberculosis
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Related Questions
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How do you approach treatment of tuberculous scleritis in pregnancy?
